Clinical trial
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
NCT03911388 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 12, 2019
- Completion date
- September 1, 2027
- Enrollment
- 24 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
astrocytoma, astrocytoma, cerebellar, brain diseases, central nervous system diseases, central nervous system neoplasms, malignant, central nervous system neoplasms, primary, cerebellar neoplasm malignant primary, cerebellar neoplasm, malignant, cerebellar neoplasms, cerebellar neoplasms, primary, cerebellar pnet, childhood, glioblastoma multiforme, glioblastoma of cerebellum, hsv, medulloblastoma recurrent, neoplasm malignant, neoplasm metastases, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, brain, neoplasms, germ cell and embryonal, neoplasms, glandular and epithelial, neoplasms, nerve tissue, neoplasms, neuroepithelial, nervous system cancer, nervous system diseases, nervous system neoplasms, neuroectodermal tumors, neuroectodermal tumors, primitive, pediatric brain tumor, primitive neuroectodermal tumor (pnet) of cerebellum, virus